Xeris Biopharma (XERS) COO sells 15,000 shares under 10b5-1 plan
Rhea-AI Filing Summary
Kevin McCulloch, President and Chief Operating Officer of Xeris Biopharma Holdings, Inc., sold 15,000 shares of common stock on August 3, 2026 at a weighted average price of about $8.016 per share under a Rule 10b5-1 trading plan adopted on September 4, 2025, and now reports 1,676,126 shares held directly plus 25,000 shares held indirectly through his spouse, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 15,000 shares
Net Sell
2 txns
Insider
McCulloch Kevin
Role
See Remarks
Sold
15,000 shs ($120K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2 | 15,000 | $8.016 | $120K |
| holding | Common Stock F3 | -- | -- | -- |
Holdings After Transaction:
Common Stock — 1,676,126 shares (Direct);
Common Stock — 25,000 shares (Indirect, By Spouse)
Footnotes (3)
- F1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2025.
- F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.000 to $8.150, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Key Figures
Shares sold: 15000 shares
Weighted average sale price: 8.0160 per share
Direct holdings after transaction: 1676126 shares
+2 more
5 metrics
Shares sold
15000 shares
Common stock sale on August 3, 2026
Weighted average sale price
8.0160 per share
Weighted average for shares sold; individual trades ranged from $8.000 to $8.150
Direct holdings after transaction
1676126 shares
Common stock directly held by Kevin McCulloch after the sale
Indirect spouse holdings
25000 shares
Shares reported as held indirectly "By Spouse" with beneficial ownership disclaimed except for pecuniary interest
10b5-1 plan adoption date
September 4, 2025
Date Kevin McCulloch adopted the Rule 10b5-1 trading plan used for this sale
Key Terms
Rule 10b5-1 trading plan, weighted average price, beneficial ownership, pecuniary interest, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported is a weighted average price. These shares were sold in multiple transactions"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
beneficial ownership regulatory
"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein"
indirect ownership financial
"total_shares_following_transaction 25000.0000, direct_or_indirect I, nature_of_ownership By Spouse"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did XERS report for Kevin McCulloch?
Xeris Biopharma (XERS) reported that Kevin McCulloch, its President and Chief Operating Officer, sold 15,000 shares of common stock on August 3, 2026 at a weighted average price of about $8.016 per share, pursuant to a Rule 10b5-1 trading plan.
At what price did the XERS insider sale by Kevin McCulloch occur?
The reported sale used a weighted average price of $8.016 per share. A footnote states that the 15,000 shares were sold in multiple trades at prices ranging from $8.000 to $8.150, and full price-by-trade details are available on request.
Was the XERS insider trade made under a Rule 10b5-1 plan?
Yes. A footnote explains the transaction was effected under a Rule 10b5-1 trading plan adopted by Kevin McCulloch on September 4, 2025. The filing’s Rule 10b5-1 checkbox is also marked, indicating the sale followed a pre-established trading arrangement.